Physician profile
Cody D Quarnberg
NPI 1902977655
$5,004.88
in general payments reported to CMS, 2019-2025
31 companies · $930 in 2025
The $930 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $717 · 2021: $679 · 2022: $664 · 2023: $371 · 2024: $683 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948 · Education: $36.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.04 |
| Education | $36.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $864.50 | 2019-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $371.59 | 2020-2024 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $371.07 | 2019-2021 | |
| Dompe US, INC. | $349.08 | 2019-2025 | Oxervate |
| Allergan, INC. | $291.69 | 2019-2021 | |
| Abbvie INC. | $282.98 | 2023-2025 | |
| Alcon Vision LLC | $266.95 | 2022-2025 | Rocklatan, Tryptyr |
| Aerie Pharmaceuticals, INC. | $244.55 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $202.48 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Tarsus Pharmaceuticals, INC. | $185.09 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $176.30 | 2022-2025 | Tyrvaya, Ryzumvi |
| Mallinckrodt Enterprises LLC | $173.55 | 2019 | |
| Eyevance Pharmaceuticals LLC | $152.41 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $152.02 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $149.16 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $145.60 | 2019 | |
| Thea Pharma INC. | $121.19 | 2023-2025 | Iyuzeh |
| Harrow Eye, LLC | $106.26 | 2025 | Vevye |
| Horizon Therapeutics Plc | $80.76 | 2019-2021 | |
| Amgen INC. | $80.43 | 2024-2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $45.50 | 2024 | Purified Cortrophin Gel |
| Glaukos Corporation | $41.11 | 2025 | Idosetr |
| Tearlab Corp | $23.81 | 2023 | Tearlab Osmolarity System |
| Celularity INC. | $18.46 | 2021 | |
| Sight Sciences, INC. | $18.30 | 2021 | |
| Astellas Pharma US INC | $17.79 | 2024 | Izervay |
| Biotissue Holdings INC. | $17.47 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $15.51 | 2019 | |
| Ocular Therapeutix, INC. | $14.43 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $12.50 | 2020 | |
| Akorn Operating Company LLC | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Quarnberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.